Compare Stocks: GELS, ABVC, VIRI, and KYNB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.06 -2.1%	$1.37	$0.88 ▼ $3.40	$27.48M	0.54	103,943 shs	9,983 shs
GELS Gelteq	$0.60 +8.9%	$0.65	$0.39 ▼ $2.02	$6.43M	-0.55	2.02 million shs	2,239 shs
KYNB Kyntra Bio	$6.86 +1.0%	$7.07	$6.32 ▼ $12.60	$27.76M	0.96	10,955 shs	5,698 shs
VIRI Virios Therapeutics	$1.54 -0.6%	$1.54	$0.13 ▼ $1.04	$29.66M	1.58	1.05 million shs	67,113 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+6.93%	-10.00%	-31.65%	+4.85%	-62.50%
GELS Gelteq	-4.29%	-25.84%	-17.76%	-14.57%	-70.22%
KYNB Kyntra Bio	+0.15%	-3.96%	-10.07%	-6.60%	+678,999,900.00%
VIRI Virios Therapeutics	-0.65%	+5.48%	-13.48%	+14.07%	-68.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.06 -2.1%	$1.37	$0.88 ▼ $3.40	$27.48M	0.54	103,943 shs	9,983 shs
GELS Gelteq	$0.60 +8.9%	$0.65	$0.39 ▼ $2.02	$6.43M	-0.55	2.02 million shs	2,239 shs
KYNB Kyntra Bio	$6.86 +1.0%	$7.07	$6.32 ▼ $12.60	$27.76M	0.96	10,955 shs	5,698 shs
VIRI Virios Therapeutics	$1.54 -0.6%	$1.54	$0.13 ▼ $1.04	$29.66M	1.58	1.05 million shs	67,113 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+6.93%	-10.00%	-31.65%	+4.85%	-62.50%
GELS Gelteq	-4.29%	-25.84%	-17.76%	-14.57%	-70.22%
KYNB Kyntra Bio	+0.15%	-3.96%	-10.07%	-6.60%	+678,999,900.00%
VIRI Virios Therapeutics	-0.65%	+5.48%	-13.48%	+14.07%	-68.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
GELS Gelteq	1.00	Sell	N/A	N/A
KYNB Kyntra Bio	2.60	Moderate Buy	$32.50	373.97% Upside
VIRI Virios Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GELS, ABVC, VIRI, and KYNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/6/2026	KYNB Kyntra Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
6/26/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/9/2026	KYNB Kyntra Bio	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/7/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/1/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A
GELS Gelteq	$165.65K	38.80	N/A	N/A	$1.08 per share	0.56
KYNB Kyntra Bio	$7.44M	3.73	N/A	N/A	($4.20) per share	-1.63
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.40	N/A	N/A	N/A	N/A	-62.46%	-39.99%	8/18/2026 (Estimated)
GELS Gelteq	-$4.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	$183.45M	$40.46	0.17	N/A	N/A	2,199.13%	N/A	-36.71%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A

Latest GELS, ABVC, VIRI, and KYNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	N/A	N/A	N/A	$0.11 million	N/A
6/30/2026	Q2 2026	GELS Gelteq	N/A	-$0.12	N/A	-$0.12	N/A	N/A
5/18/2026	Q1 2026	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.12	0.12
GELS Gelteq	N/A	0.09	N/A
KYNB Kyntra Bio	N/A	3.61	3.48
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
GELS Gelteq	N/A
KYNB Kyntra Bio	72.71%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
GELS Gelteq	N/A
KYNB Kyntra Bio	4.15%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.00 million	21.06 million	Not Optionable
GELS Gelteq	N/A	10.71 million	N/A	N/A
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
VIRI Virios Therapeutics	5	19.26 million	16.91 million	No Data

GELS, ABVC, VIRI, and KYNB Headlines

Recent News About These Companies

Digital acceptance and commitment therapy for fibromyalgia – Authors' reply

June 13, 2025 | thelancet.comT

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 21, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.comA

Dogwood Therapeutics faces potential Nasdaq delisting

November 23, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, ABVC, VIRI, and KYNB Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.06 -0.02 (-2.22%)

As of 10:07 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Gelteq NASDAQ:GELS

$0.60 +0.05 (+8.89%)

As of 10:06 AM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Kyntra Bio NASDAQ:KYNB

$6.86 +0.07 (+0.99%)

As of 10:01 AM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Virios Therapeutics NASDAQ:VIRI

$1.54 -0.01 (-0.65%)

As of 07/29/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GELS, ABVC, VIRI, and KYNB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GELS, ABVC, VIRI, and KYNB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GELS, ABVC, VIRI, and KYNB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, ABVC, VIRI, and KYNB Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Gelteq NASDAQ:GELS

Kyntra Bio NASDAQ:KYNB

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GELS, ABVC, VIRI, and KYNB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GELS, ABVC, VIRI, and KYNB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GELS, ABVC, VIRI, and KYNB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, ABVC, VIRI, and KYNB Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Gelteq NASDAQ:GELS

Kyntra Bio NASDAQ:KYNB

Virios Therapeutics NASDAQ:VIRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools